OPK's Quality Score rose 2 points on Mon, Nov 2, to 11. Its price got close to its high of the past year (2 chart checks started).
Follow OPK's trial news. Pro members can get an alert when Opko Health files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 3.6% today, while its drugmaker peers are down 1.7%; no story names it yet.
Rose on Oct 15
Up 18% on Oct 15, and still 21% over its Oct 14 close.
| Since its Dec 2021 high | Down 68% |
| Latest filing | 8-K, Oct 15 |
TodayNo story names it yet.
After its last 4 reports it closed +6.7% on average, higher 2 of 4 times.
About 9 quarters
No shelf registration or at-the-market program on file in the last three years.
Director John A Paganelli bought 10,000 shares on Mar 20.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. OPK scores 11 today, against a median of 6.5 over its last 20 recorded sessions.
OPK is #13 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 13 |
Reports Wed Nov 4, after the close (in 2 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Consolidated total revenues for the second quarter of 2026 were $163.5 million compared with $156.8 million for the 2025 period, with the increase principally resulting from higher revenue from the transfer of intellectual property and other, partially offset by lower revenue from services following the September 2025 sale of our oncology assets to Labcorp.”
OPK's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
Sales fell 16% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 3.2% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Jul 27, 2026 | +11.3% | +33.1% | +5.7% |
| Apr 28, 2026 | -3.3% | -8.3% | -6.6% |
| Feb 26, 2026 | -0.8% | 0.0% | -2.5% |
Sales grew in two of the last seven years, to $607M in 2025. It made a profit in one of the eight years.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: OPK is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
“The pharmaceutical and diagnostic testing industries are highly competitive and require an ongoing, extensive search for technological innovation.”
OPK scores 11 today, which Breakaway calls Above Average. It is #13 of 92 in Pharma by Quality Score, with 8 of 14 chart checks firing. Up 18% on Oct 15, and still 21% over its Oct 14 close. Cash lasts about 9 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
OPK scores 11 today, which Breakaway calls Above Average (11 to 14). That is #13 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind OPK's 11.
Reports Wed Nov 4, after the close, a date the company confirmed. OPK closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.